The effects of CYP2C9 and VKORC1 gene polymorphisms on warfarin maintenance dose in Turkish cardiac patients

AKDENİZ C. S., ÇEVİK M., CANBOLAT İ. P., YURDAKUL S., ÇAĞATAY P., ÇİFTÇİ Ç., ...Daha Fazla

FUTURE CARDIOLOGY, cilt.16, ss.645-654, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 16
  • Basım Tarihi: 2020
  • Doi Numarası: 10.2217/fca-2020-0027
  • Dergi Adı: FUTURE CARDIOLOGY
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Chemical Abstracts Core, CINAHL, EMBASE, MEDLINE
  • Sayfa Sayıları: ss.645-654
  • Anahtar Kelimeler: 9041 G > A, CYP2C9, pharmacogenetics, VKORC1, warfarin
  • Marmara Üniversitesi Adresli: Evet

Özet

Aim: Our aim was to examine the effect of CYP2C9 and VKORC1 polymorphisms on warfarin dose requirements in Turkish patients. Materials & methods: 24 warfarin prescribed patients were included and analyzed for eight VKORC1 and 6 CYP2C9 polymorphisms in the study. Results: Patients with CYP2C9 *1/*1 and VKORC1 -1639 GG and GA genotypes required higher warfarin doses in comparison to wild type VKORC1 genotype. Patients with CYP2C9 *1/*3 and VKORC1 -1639 GG genotypes simultaneously, required the lowest dose of warfarin (4.64 mg/day). Patients with CYP2C9 *1/*1 and VKORC1 9041 AA genotype were found to require higher warfarin doses. Conclusion: Our results provide additional evidence to support the hypothesis that CYP2C9 *2, *3, VKORC1 9041 G > A polymorphisms explain considerable proportion of inter-individual variability in warfarin dose requirement.